Beraprost

Drug Profile

Beraprost

Alternative Names: Befraprost; Dorner; ML 129; ML-1129; ML-1229; Procyclin; RU-55100; TRK-100

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Toray
  • Developer Kaken Pharmaceutical; sanofi-aventis; Toray; United Therapeutics Corporation
  • Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Prostacyclin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Peripheral vascular disorders; Pulmonary hypertension
  • Discontinued Cancer; Diabetic neuropathies; Intermittent claudication

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 02 Aug 2002 Discontinued - Phase-III for Pulmonary hypertension in Canada (PO)
  • 02 Aug 2002 Discontinued - Phase-III for Pulmonary hypertension in the US (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top